"A phase I dose-escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) administered in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (Pts) with advanced refractory solid tumors." by Rachel E. Sanborn

Selected Works of Walter J. Urba, MD, PhD

Article

A phase I dose-escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) administered in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (Pts) with advanced refractory solid tumors.

Journal of Clinical Oncology (2017)

Rachel E. Sanborn, Providence Portland Medical Center
William Howard Sharfman, Johns Hopkins University
Neil Howard Segal, Memorial Sloan Kettering Cancer Center
F. Stephen Hodi, Harvard University
Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center
Walter John Urba
Bernard A. Fox, Providence Portland Medical Center
Suzanne Louise Topalian, Johns Hopkins University School of Medicine
Drew M. Pardoll, Johns Hopkins University School of Medicine
Kelly L. Covello, Bristol-Myers Squibb
Dan McDonald, Bristol-Myers Squibb
Su Young Kim, Bristol-Myers Squibb
Ashok Kumar Gupta, Bristol-Myers Squibb
Jon M. Wigginton, Bristol-Myers Squibb
Thomas Gajewski, University of Chicago

Link

Disciplines

Publication Date

January 30, 2017

Citation Information

Rachel E. Sanborn, William Howard Sharfman, Neil Howard Segal, F. Stephen Hodi, et al.. "A phase I dose-escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) administered in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (Pts) with advanced refractory solid tumors." Journal of Clinical Oncology (2017)
Available at: http://works.bepress.com/walter-urba/99/